A Spectral Fiedler Field-based Contrast Platform for Imaging of Nanoparticles in Colon Tumor

Simple item page
dc.contributor.authorLiu, Chenangen
dc.contributor.authorKapoor, Ankuren
dc.contributor.authorVanOsdol, Joshuaen
dc.contributor.authorEktate, Kalyanien
dc.contributor.authorKong, Zhenyuen
dc.contributor.authorRanjan, Ashishen
dc.contributor.departmentIndustrial and Systems Engineeringen
dc.date.accessioned2018-12-11T17:55:43Zen
dc.date.available2018-12-11T17:55:43Zen
dc.date.issued2018-07-30en
dc.description.abstractThe temporal and spatial patterns of nanoparticle that ferry both imaging and therapeutic agent in solid tumors is significantly influenced by target tissue movement, low spatial resolution, and inability to accurately define regions of interest (ROI) at certain tissue depths. These combine to limit and define nanoparticle untreated regions in tumors. Utilizing graph and matrix theories, the objective of this project was to develop a novel spectral Fiedler field (SFF) based-computational technology for nanoparticle mapping in tumors. The novelty of SFF lies in the utilization of the changes in the tumor topology from baseline for contrast variation assessment. Data suggest that SFF can enhance the spatiotemporal contrast compared to conventional method by 2-3 folds in tumors. Additionally, the SFF contrast is readily translatable for assessment of tumor drug distribution. Thus, our SFF computational platform has the potential for integration into devices that allow contrast and drug delivery applications.en
dc.description.notesResearch reported in this publication was supported by the Center for Veterinary Health Sciences Seed Support, National Cancer Institute of the National Institutes of Health under Award Number R15CA179369, the Oklahoma Center for Advancement in Science and Technology (OCAST), and the Oklahoma State University (OSU) Kerr Endowed chair support and Technology Business Development Program grant. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health or OCAST. The liposomes (mentioned herein) is based on research and is not commercially available. Its future availability cannot be guaranteed due to regulatory issues.en
dc.description.sponsorshipCenter for Veterinary Health Sciences Seed Support; National Cancer Institute of the National Institutes of Health [R15CA179369]; Oklahoma Center for Advancement in Science and Technology (OCAST); Oklahoma State University (OSU); Technology Business Development Program granten
dc.format.extent8 pagesen
dc.format.mimetypeapplication/pdfen
dc.identifier.doihttps://doi.org/10.1038/s41598-018-29675-1en
dc.identifier.issn2045-2322en
dc.identifier.other11390en
dc.identifier.pmid30061558en
dc.identifier.urihttp://hdl.handle.net/10919/86344en
dc.identifier.volume8en
dc.language.isoenen
dc.publisherSpringer Natureen
dc.rightsCreative Commons Attribution 4.0 Internationalen
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/en
dc.subjectintensity focused ultrasounden
dc.subjectliposomal drug-deliveryen
dc.subjectsensitive liposomesen
dc.subjectechogenic liposomesen
dc.subjectcancer theranosticsen
dc.subjectin-vivoen
dc.subjectTemperatureen
dc.subjecttherapyen
dc.subjectradiotherapyen
dc.subjectsystemsen
dc.titleA Spectral Fiedler Field-based Contrast Platform for Imaging of Nanoparticles in Colon Tumoren
dc.title.serialScientific Reportsen
dc.typeArticle - Refereeden
dc.type.dcmitypeTexten

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
s41598-018-29675-1.pdf
Size:
1.56 MB
Format:
Adobe Portable Document Format
Description:
Download

Collections

Scholarly Works, Industrial and Systems Engineering
Open Access Subvention Fund Articles
Strategic Growth Area: Economical and Sustainable Materials (ESM)